Cullinan Therapeutics is paying $20 million upfront for a BCMAxCD3 bispecific T cell engager that the biotech plans to pair ...

Zenas BioPharma has released its corporate presentation for June 2025, providing an insight into its financial and clinical ...

Patients who develop LN within 1 to 5 years after SLE onset may face poorer renal outcomes compared with those who develop the disease earlier.

The annual 10km Lupus Awareness Fun Walk took place on May 31 in Mamelodi. We Also Sparkle and Waratwa foundations held the ...

Individuals with IBD, especially CD, have an increased risk for myocardial infarction, ischemic heart disease, cerebrovascular accident, and major adverse cardiovascular events.

Research findings increasingly indicate close associations between autoimmune thyroid disease and rheumatic disease.

Belimumab, a monoclonal antibody, added to standard therapy may treat a broader range of patients with lupus nephritis than previously appreciated.